Trial Profile
A randomised, open-label, 4-period crossover, phase I clinical trial of various oral formulations of omecamtiv mecarbil in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Jan 2016
Price :
$35
*
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Angina pectoris; Cardiomyopathies; Heart failure
- Focus Pharmacokinetics
- 28 Dec 2015 Results published in the International Journal of Clinical Pharmacology and Therapeutics
- 01 Jul 2012 Status changed from recruiting to completed.
- 21 Feb 2012 Planned number of subjects is 60, according to a Cytokinetics Media release.